Marine natural products: Bryostatins in preclinical and clinical studies

References

• Al-Katib AM, Smith MR, Kamanda WS, et al. (1998). Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 4:1305–14
   PubMed Web of Science ®Google Scholar
• Baldwin NG, Rice CD, Tuttle TM, et al. (1997). Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes. J Neurooncol 32:19–28
   PubMed Web of Science ®Google Scholar
• Banerjee S, Wang Z, Mohammad M, et al. (2008). Efficacy of selected natural products as therapeutic agents against cancer. J Nat Prod 71:492–6
   PubMedGoogle Scholar
• DeChristopher BA, Fan AC, Felsher DW, Wender PA. (2012). “Picolog,” a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo. Oncotarget 3:58–66
   PubMedGoogle Scholar
• Dunlap WC, Battershill CN, Liptrot CH, et al. (2007). Biomedicinals from the phytosymbionts of marine invertebrates: A molecular approach. Methods 42:358–76
   PubMed Web of Science ®Google Scholar
• Haygood MG, Schmidt EW, Davidson SK, Faulkner DJ. (1999). Microbial symbionts of marine invertebrates: Opportunities for microbial biotechnology. J Mol Microbiol Biotechnol 1:33–43
   PubMedGoogle Scholar
• Hayun M, Okun E, Hayun R, et al. (2007). Synergistic effect of AS101 and bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model. Leukemia 21:1504–13
   PubMed Web of Science ®Google Scholar
• Huang MQ, Nelson DS, Pickup S, et al. (2007). In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS. Acad Radiol 14:1531–9
   PubMedGoogle Scholar
• Jayson GC, Crowther D, Prendiville J, et al. (1995). A phase-I trial of bryostatin 1 in patients with advanced malignancy using a 24-hour intravenous infusion. Br J Cancer 72:461–8
   PubMed Web of Science ®Google Scholar
• Jiangbo Z, Xuying W, Yuping Z, et al. (2010). Toxicity of bryostatin-1 on the embryo-fetal development of Sprague-Dawley rats. Birth Defects Res B Dev Reprod Toxicol 89:171–4
   PubMedGoogle Scholar
• Kraft AS, Woodley S, Pettit GR, et al. (1996). Comparison of the antitumor activity of bryostatins 1, 5, and 8. Cancer Chemother Pharmacol 37:271–8
   PubMed Web of Science ®Google Scholar
• Kuzirian AM, Epstein HT, Gagliardi CJ, et al. (2006). Bryostatin enhancement of memory in Hermissenda. Biol Bull 210:201–14
   PubMedGoogle Scholar
• Manning TJ, Land M, Rhodes E, et al. (2005). Identifying bryostatins and potential precursors from the bryozoan Bugula neritina. Nat Prod Res 19:467–91
   PubMed Web of Science ®Google Scholar
• Mehla R, Bivalkar-Mehla S, Zhang R, et al. (2010). Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS ONE 5:e11160. Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0011160 [last accessed 19 Nov 2012]
   PubMed Web of Science ®Google Scholar
• Mohammad RM, Varterasian ML, Almatchy VP, et al. (1998a). Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1. Clin Cancer Res 4:1337–43
   PubMed Web of Science ®Google Scholar
• Mohammad RM, Katato K, Almatchy VP, et al. (1998b). Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: Preclinical studies. Clin Cancer Res 4:445–53
   PubMed Web of Science ®Google Scholar
• Mohammad RM, Li Y, Mohamed AN, et al. (1999a). Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma. Pancreas 19:353–61
   PubMedGoogle Scholar
• Mohammad RM, Limvarapuss C, Hamdy N, et al. (1999b). Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine. Int J Oncol 14:945–50
   PubMed Web of Science ®Google Scholar
• National Institutes of Health (NIH): Safety, efficacy, pharmacokinetics, and pharmacodynamics study of bryostatin 1 in patients with Alzheimer's disease. Available from: http://clinicaltrials.gov/ct2/show/NCT00606164 [last accessed 19 Nov 2012]
   Google Scholar
• Newman DJ. (2012). The bryostatins. In: Cragg GM, Kingston DGI, Newman DJ, eds. Anticancer Agents from Natural Products. Boca Raton: Taylor and Francis, 199–218
   Google Scholar
• Oz HS, Hughes WT, Rehg JE, Thomas EK. (2000). Effect of CD40 ligand and other immunomodulators on Pneumocystis carinii infection in rat model. Microb Pathog 29:187–90
   PubMed Web of Science ®Google Scholar
• Parviz M, Chin CS, Graham LJ, et al. (2003). Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer Immunol Immunother 52:739–50
   PubMed Web of Science ®Google Scholar
• Piel J. (2006). Bacterial symbionts: Prospects for the sustainable production of invertebrate-derived pharmaceuticals. Curr Med Chem 13:39–50
   PubMed Web of Science ®Google Scholar
• Prendiville J, Crowther D, Thatcher N, et al. (1993). A phase-I study of intravenous bryostatin-1 in patients with advanced cancer. Br J Cancer 68:418–24
   PubMed Web of Science ®Google Scholar
• Propper DJ, Macaulay V, O'Byrne KJ, et al. (1998). A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 78:1337–41
   PubMed Web of Science ®Google Scholar
• da Rocha AB, Lopes RM, Schwartsmann G. (2001). Natural products in anticancer therapy. Curr Opin Pharmacol 1:364–9
   PubMedGoogle Scholar
• Schaufelberger DE, Koleck MP, Beutler JA, et al. (1991). The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices. J Nat Prod 54:1265–70
   PubMed Web of Science ®Google Scholar
• Schwartsmann G, da Rocha AB, Berlinck RG, Jimeno J. (2001). Marine organisms as a source of new anticancer agents. Lancet Oncol 2:221–5
   PubMed Web of Science ®Google Scholar
• Trindade-Silva AE, Lim-Fong GE, Sharp KH, Haygood MG. (2010). Bryostatins: Biological context and biotechnological prospects. Curr Opin Biotech 21:834–42
   PubMedGoogle Scholar
• Trost BM, Yang H, Dong G. (2011). Total syntheses of bryostatins: Synthesis of two ring-expanded bryostatin analogues and the development of a new-generation strategy to access the C7–C27 fragment. Chemistry 17:9789–805
   PubMedGoogle Scholar
• Ueno S, Yanagita RC, Murakami K, et al. (2012). Identification and biological activities of bryostatins from Japanese Bryozoan. Biosci Biotechnol Biochem 76:1041–3
   PubMed Web of Science ®Google Scholar
• Wender PA, Hinkle KW, Koehler MF, Lippa B. (1999). The rational design of potential chemotherapeutic agents: Synthesis of bryostatin analogues. Med Res Rev 19:388–407
   PubMed Web of Science ®Google Scholar
• Wender PA, Horan JC, Verma VA. (2006). Total synthesis and initial biological evaluation of new B-ring-modified bryostatin analogues. Org Lett 8:5299–302
   PubMedGoogle Scholar
• Wender PA, Verma VA. (2008). The design, synthesis, and evaluation of C7 diversified bryostatin analogues reveals a hot spot for PKC affinity. Org Lett 10:3331–4
   PubMedGoogle Scholar
• Zhang X, Zhang R, Zhao H, et al. (1996). Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res 56:802–8
   PubMed Web of Science ®Google Scholar